Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE – Get Free Report) saw a significant decrease in short interest in the month of July. As of July 31st, there was short interest totaling 21,094 shares, a decrease of 44.5% from the July 15th total of 38,037 shares. Based on an average daily trading volume, of 10,788 shares, the days-to-cover ratio is presently 2.0 days. Approximately 0.4% of the company’s shares are short sold.
Hedge Funds Weigh In On Alterity Therapeutics
A hedge fund recently bought a new position in Alterity Therapeutics stock. Citadel Advisors LLC purchased a new stake in Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE – Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 22,144 shares of the company’s stock, valued at approximately $83,000. Citadel Advisors LLC owned 0.25% of Alterity Therapeutics at the end of the most recent quarter. 2.14% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
Several equities analysts recently issued reports on the stock. UBS Group set a $12.00 target price on shares of Alterity Therapeutics in a report on Tuesday, August 11th. Zacks Research raised Alterity Therapeutics to a “hold” rating in a research report on Wednesday, June 17th. Weiss Ratings reissued a “sell (e+)” rating on shares of Alterity Therapeutics in a research note on Friday, July 17th. Craig Hallum set a $2.00 target price on Alterity Therapeutics in a research report on Tuesday, August 11th. Finally, LADENBURG THALM/SH SH began coverage on Alterity Therapeutics in a research note on Tuesday, June 16th. They set a “buy” rating and a $10.00 target price for the company. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $10.00.
Alterity Therapeutics Stock Performance
Alterity Therapeutics stock traded up $0.02 during midday trading on Tuesday, reaching $4.59. The stock had a trading volume of 3,339 shares, compared to its average volume of 27,328. The company has a fifty day moving average price of $4.84 and a two-hundred day moving average price of $4.17. Alterity Therapeutics has a 12 month low of $2.66 and a 12 month high of $5.89.
Alterity Therapeutics Company Profile
Alterity Therapeutics is a clinical-stage biotechnology company focused on the development of novel treatments for neurological and neurodegenerative disorders. The company’s research portfolio centers on small molecules designed to target underlying disease mechanisms, with an emphasis on improving synaptic function and mitigating neuroinflammation.
Among its lead assets is trofinetide (NNZ-2566), a peptide analog derived from insulin-like growth factor 1, which is being investigated for the treatment of Rett syndrome and Fragile X syndrome in ongoing clinical trials.
Featured Stories
- Five stocks we like better than Alterity Therapeutics
- The AI Boom Is Turning This Cable Maker Into a Stock to Watch
- A Star Investor Just Trimmed Amazon—Here’s What It means
- Wendy’s Deal Buzz May Give Fast-Food Investors a New Reason to Look
- Home Depot Analysts See a Path to $375 and Beyond
Receive News & Ratings for Alterity Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alterity Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
